| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Blomqvist, M, et al.
(author)
-
Identification of defensins in human lymphocyte nuclei
- 1999
-
In: EUROPEAN JOURNAL OF BIOCHEMISTRY. - : BLACKWELL SCIENCE LTD. - 0014-2956. ; 263:2, s. 312-318
-
Journal article (other academic/artistic)abstract
- The cell nucleus plays an essential role in all aspects of cell function and regulation. Most of the nuclear proteins/ peptides are synthesized in the cytoplasm. and transported into the nucleus through the nuclear pore complexes. The nuclear proteins/pep
|
|
| 5. |
- Blomqvist, M, et al.
(author)
-
Identification of defensins in human lymphocyte nuclei
- 1999
-
In: European Journal of Biochemistry. - : Wiley. - 0014-2956 .- 1432-1033. ; 263:2, s. 312-8
-
Journal article (peer-reviewed)abstract
- The cell nucleus plays an essential role in all aspects of cell function and regulation. Most of the nuclear proteins/peptides are synthesized in the cytoplasm and transported into the nucleus through the nuclear pore complexes. The nuclear proteins/peptides conjugate with each other and interact in transcriptional activation/inactivation. Several of the high molecular mass transcription factors (> 30 kDa) have been identified and characterized. However, the information on the low molecular mass proteins/peptides of the nucleus is limited. We have investigated these low molecular mass proteins/peptides from the nucleus of human peripheral blood lymphocytes using reversed-phase high-performance liquid chromatography (RP-HPLC). The HPLC fractions were further analysed by matrix assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry, electrospray ionization time of flight (ESI-TOF) mass spectrometry and electrospray ionization fourier transform ion cyclotron resonance (ESI-FTICR) mass spectrometry for mass determination. Using this combination of mass spectrometry techniques and microsequence analysis, we have shown that human lymphocyte nuclei contain defensins, a mixture of human neutrophil granule peptide 1, 2 and 3.
|
|
| 6. |
|
|
| 7. |
- Falconer, C, et al.
(author)
-
Changes in paraurethral connective tissue at menopause are counteracted by estrogen
- 1996
-
In: Maturitas. - 0378-5122. ; 24:3, s. 197-204
-
Journal article (peer-reviewed)abstract
- OBJECTIVE: To study whether the transition to menopause is accompanied by changes in the paraurethral connective tissue and if these changes are modified by estrogen replacement therapy.STUDY DESIGN: Biopsies were obtained from the paraurethral tissue from 34 women; 12 menstruating, 14 postmenopausal without estrogen treatment, and 8 with estrogen treatment. Collagen concentration and collagen extractability by pepsin digestion were measured. Proteoglycan composition and concentration were analysed using Alcian blue. The mRNA levels for collagen I and III, the small proteoglycans (PGS) decorin and biglycan, and the large proteoglycan versican, were estimated.RESULTS: The paraurethral biopsies consisted of fibrous connective tissue, with collagen fibers as dominating structure. Several proteoglycans were identified; versican, heparansulphate proteoglycans, biglycan and decorin. The small proteoglycan decorin represented 85% of all proteoglycans. The collagen concentration was almost doubled in postmenopausal biopsies compared to premenopausal. The collagen fibril organization was also changed with higher cross-linking after menopause whereas the amount and the composition of the proteoglycans were unchanged. The proteoglycan/collagen ratio was significantly decreased. Estrogen replacement therapy resulted in decreased collagen concentration, decreased cross-linking of the collagen and reversal of the PGS/collagen ratio to almost premenopausal level. The therapy resulted in increased levels of mRNA for collagen I and III which suggests that the changes are due to an increased turnover.CONCLUSION: The decrease in estrogen levels at menopause results in a connective tissue with different qualities after menopause. Estrogen replacement therapy tends to restore the metabolism of the genitourinary connective tissue to premenopausal conditions.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
